Pb2482: Roxadustat Suppresses Adipogenesis in Human BMMSC and Promotes Epo Production via Regulation of Hif Signaling Pathways

Abstract

Background:Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, has been used to treat anemia in patients with chronic kidney diseases by increasing erythroprotein(EPO) levels. EPO is an important cytokine required for hematopoiesis which is also secreted by bone marrow niche. Roxadustat is reported closed with the HIF signaling pathways, which is also important for regulation of EPO production. However, there is few data about the effects of roxadustat on the bone marrow microenvironment.